DE69822300D1 - 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen - Google Patents

3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen

Info

Publication number
DE69822300D1
DE69822300D1 DE69822300T DE69822300T DE69822300D1 DE 69822300 D1 DE69822300 D1 DE 69822300D1 DE 69822300 T DE69822300 T DE 69822300T DE 69822300 T DE69822300 T DE 69822300T DE 69822300 D1 DE69822300 D1 DE 69822300D1
Authority
DE
Germany
Prior art keywords
pyridyl
aza
bicyclo
azabicycloalkan
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69822300T
Other languages
English (en)
Other versions
DE69822300T2 (de
Inventor
Scott Caldwell
Merouane Bencherif
Maurice Dull
Anthony Crooks
Michael Lippiello
Singh Bhatti
Madhukar Deo
Alain Ravard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalyst Biosciences Inc
Original Assignee
University of Kentucky Research Foundation
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/885,397 external-priority patent/US6525065B1/en
Priority claimed from US08/885,768 external-priority patent/US6624173B1/en
Application filed by University of Kentucky Research Foundation, Targacept Inc filed Critical University of Kentucky Research Foundation
Application granted granted Critical
Publication of DE69822300D1 publication Critical patent/DE69822300D1/de
Publication of DE69822300T2 publication Critical patent/DE69822300T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69822300T 1997-06-30 1998-04-22 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen Expired - Fee Related DE69822300T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US885768 1997-06-30
US885397 1997-06-30
US08/885,397 US6525065B1 (en) 1997-06-30 1997-06-30 Pharmaceutical compositions and methods for effecting dopamine release
US08/885,768 US6624173B1 (en) 1997-06-30 1997-06-30 Pharmaceutical compositions for treating and/or preventing CNS disorders
PCT/US1998/008145 WO1999000385A1 (en) 1997-06-30 1998-04-22 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cns disorders

Publications (2)

Publication Number Publication Date
DE69822300D1 true DE69822300D1 (de) 2004-04-15
DE69822300T2 DE69822300T2 (de) 2005-03-10

Family

ID=27128761

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69822300T Expired - Fee Related DE69822300T2 (de) 1997-06-30 1998-04-22 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen

Country Status (10)

Country Link
EP (1) EP0994875B1 (de)
JP (1) JP2002511090A (de)
AT (1) ATE261443T1 (de)
AU (1) AU7149798A (de)
CA (1) CA2294990C (de)
DE (1) DE69822300T2 (de)
DK (1) DK0994875T3 (de)
ES (1) ES2214707T3 (de)
PT (1) PT994875E (de)
WO (1) WO1999000385A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
EP1225955A1 (de) * 1999-11-01 2002-07-31 Targacept, Inc. Aryl-olefinische-azacyclische, und aryl-acetylen-azacyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als inhibitoren von nikotin cholinergen rezeptoren
CA2420235A1 (en) * 2000-08-21 2002-02-28 Georgetown University 2-3-disubstituted quinuclidines as modulators of monoamine transporters and therapeutic and diagnostic methods based thereon
US6710048B2 (en) 2000-09-20 2004-03-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
JP4923630B2 (ja) * 2006-03-02 2012-04-25 宇部興産株式会社 ４−置換テトラヒドロピランの製造方法
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5413441B2 (ja) * 2011-12-09 2014-02-12 宇部興産株式会社 ４−置換テトラヒドロピランの製造方法
CN104311514B (zh) * 2014-10-14 2016-06-22 安徽扬子化工有限公司 3-羟甲基四氢呋喃酯的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412798A3 (en) * 1989-08-08 1992-07-01 Merck Sharp & Dohme Ltd. Substituted pyridines, their preparation, formulations and use in dementia
US5242935A (en) * 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
AU7474794A (en) * 1993-07-22 1995-02-20 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
US5510355A (en) * 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
WO1996036637A1 (en) * 1995-05-17 1996-11-21 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
EP0994875A1 (de) 2000-04-26
EP0994875B1 (de) 2004-03-10
ES2214707T3 (es) 2004-09-16
PT994875E (pt) 2004-06-30
JP2002511090A (ja) 2002-04-09
DE69822300T2 (de) 2005-03-10
ATE261443T1 (de) 2004-03-15
CA2294990A1 (en) 1999-01-07
CA2294990C (en) 2007-03-06
AU7149798A (en) 1999-01-19
WO1999000385A1 (en) 1999-01-07
DK0994875T3 (da) 2004-06-21

Similar Documents

Publication Publication Date Title
Maelicke et al. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
SI1678172T1 (sl) AzabicikliŽŤne spojine za lajšanje boleŽŤine in zdravljenje motenj centralnega ĹľivŽŤnega sistema
WO2004108668A3 (en) Alpha-7 neuronal nicotinic receptor ligands: compositions and methods of use
DE60045427D1 (de) Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE69822300D1 (de) 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
PH31335A (en) Naphthalamides as central nervous system agent.
NO20041166L (no) Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament
WO2006040451A3 (fr) Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
TW200531680A (en) Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
DE68912419D1 (de) Verwendung von Uridin zur Behandlung nervöser Störungen.
AP2002002465A0 (en) Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or Vitamin E for the treatment of cognitive disorders.
IL192287A0 (en) Pharmaceutical compositions and methods for use
TW200735868A (en) Compositions and methods for treating CNS disorders
TNSN99177A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1, 2-a] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
AU4038000A (en) 4-substituted quinoline derivatives as gaba receptor ligands
NZ515613A (en) Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
HK1098670A1 (en) Use of 3-aza-1-oxa-dibenzo Äe,hÜ azulenes for the manufacture of pharmaceutical formulations for thetreatment and prevention of central nervous syste m disease and disorders

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TARGACEPT, INC., WINSTON-SALEM, N.C., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee